


# Rapid Depression Relief with SPRAVATO®

The Only FDA-Approved Nasal Spray Treatment for TRD



## Treat Depression with a Different Approach

- FDA-approved
- Safe and effective
- Can reduce depression symptoms in as little as 24 hours<sup>1</sup>



SPRAVATO® (esketamine) nasal spray is an NMDA receptor antagonist that is believed to work differently by acting on a pathway in the brain that affects glutamate.<sup>2</sup>

SPRAVATO® is indicated for the treatment of:

- Treatment-resistant depression (TRD)<sup>3</sup> in adults as monotherapy or in conjunction with an oral antidepressant.
- Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.

## Proven Effective for TRD

In a short-term study, more patients using SPRAVATO® plus oral antidepressant demonstrated rapid and significantly greater reduction in depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant.<sup>4</sup>



## Transforming TRD with Evidence and Experience

SPRAVATO® has been administered to more than 100,000 patients in the US.<sup>5</sup> Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO® has proven to be a transformational treatment option for many patients with TRD.

## Covered by Many Major Insurances

Many major insurance companies cover SPRAVATO® for patients who haven't found adequate relief after trying just two oral antidepressants.

### Typical Insurance Criteria\*

- ✓ 18+ years old
- ✓ MDD diagnosis
- ✓ 2+ antidepressant trials
- ✓ No history of psychosis

\*Specific insurance criteria may differ based on policies of applicable payers



## SPRAVATO® Treatment Phases\*\*

Induction	Maintenance Phase 1	Maintenance Phase 2
Week 1-4 Twice Weekly	Week 5-8 Once Weekly	Week 9+ Once Every 1-2 Weeks

Each treatment session is two hours

\*\*Treatment plans may vary depending on clinical condition

### References

1. Based on results of SPRAVATO® short-term clinical study; additional details available in the Prescribing Information insert
2. The exact way SPRAVATO® works is not fully understood
3. Treatment Resistant Depression defined as inadequate response to two or more oral antidepressants
4. Popova, V., et al. (2019). "Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study." *Am J Psychiatry* 176(6): 428-438. 2019 Oct 1;22(10):616-630
5. Janssen Pharmaceuticals, Inc., Data on file, 2025.

CONTACT US TO REFER A PATIENT FOR A NO-COST CONSULTATION

Phone: (855) 494-4867 | Fax: (855) 721-4867

GreenbrookProviders.com

See next page for indications and safety information

